PTEN and glioblastoma: Loss or mutations of PTEN correlate with poor patient outcome in GBM [94, 95], and depending on the study, PTEN is mutated in 5-40% of glioblastoma patients, and loss of heterozygosity can be observed in up to 90% of cases [96–100].